CORONA Remedies Limited (NSE:CORONA)
India · Delayed Price · Currency is INR 1,388.30
-70.50 (-4.83%)
At close: Jan 21, 2026
CORONA Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 12,990 | 11,964 | 10,145 | 8,841 | 6,173 | 5,762 | |
Revenue Growth (YoY) | - | 17.94% | 14.75% | 43.20% | 7.14% | - |
Cost of Revenue | 2,531 | 2,431 | 2,333 | 2,156 | 1,495 | 1,460 |
Gross Profit | 10,460 | 9,533 | 7,812 | 6,685 | 4,678 | 4,302 |
Selling, General & Admin | 4,793 | 4,507 | 3,857 | 3,398 | 2,923 | 2,201 |
Other Operating Expenses | 2,940 | 2,619 | 2,394 | 2,004 | 1,576 | 1,047 |
Operating Expenses | 8,112 | 7,498 | 6,534 | 5,606 | 4,704 | 3,407 |
Operating Income | 2,348 | 2,035 | 1,278 | 1,079 | -25.87 | 895.02 |
Interest Expense | -82.59 | -103.59 | -138.81 | -39.28 | -45.46 | -17.82 |
Interest & Investment Income | 44.18 | 44.18 | 46.65 | 59.75 | 52.41 | 36.42 |
Earnings From Equity Investments | 3.65 | 3.85 | 0.06 | 2.28 | - | - |
Currency Exchange Gain (Loss) | 6.69 | 6.69 | 4.87 | 5.62 | 4.25 | 1.89 |
Other Non Operating Income (Expenses) | 9.22 | 3.82 | 1.47 | -1.28 | 5.71 | 1.11 |
EBT Excluding Unusual Items | 2,329 | 1,990 | 1,192 | 1,106 | -8.96 | 916.62 |
Gain (Loss) on Sale of Investments | 0.2 | 0.2 | 2.56 | 2.46 | 1.01 | 7.71 |
Gain (Loss) on Sale of Assets | -7.05 | -7.05 | -12.05 | -0.2 | - | - |
Other Unusual Items | 1.92 | 1.92 | 1.93 | 0.56 | - | - |
Pretax Income | 2,324 | 1,985 | 1,185 | 1,109 | -7.95 | 924.33 |
Income Tax Expense | 573.39 | 490.99 | 279.78 | 259.58 | -3.95 | 224.87 |
Net Income | 1,750 | 1,494 | 905.03 | 849.29 | -4 | 699.46 |
Net Income to Common | 1,750 | 1,494 | 905.03 | 849.29 | -4 | 699.46 |
Net Income Growth | - | 65.11% | 6.56% | - | - | - |
Shares Outstanding (Basic) | 61 | 61 | 61 | 58 | 51 | 51 |
Shares Outstanding (Diluted) | 61 | 61 | 61 | 58 | 51 | 61 |
Shares Change (YoY) | -0.04% | - | 4.89% | 14.21% | -16.53% | - |
EPS (Basic) | 28.62 | 24.43 | 14.80 | 14.57 | -0.08 | 13.70 |
EPS (Diluted) | 28.62 | 24.43 | 14.80 | 14.57 | -0.08 | 11.44 |
EPS Growth | - | 65.09% | 1.59% | - | - | - |
Free Cash Flow | 1,158 | 988.48 | -1,296 | 79.42 | 636.98 | 345.16 |
Free Cash Flow Per Share | 18.94 | 16.16 | -21.19 | 1.36 | 12.48 | 5.64 |
Dividend Per Share | - | 7.310 | 3.700 | 2.770 | 1.140 | 1.143 |
Dividend Growth | - | 97.57% | 33.57% | 142.98% | -0.26% | - |
Gross Margin | 80.52% | 79.68% | 77.00% | 75.61% | 75.78% | 74.66% |
Operating Margin | 18.07% | 17.01% | 12.60% | 12.21% | -0.42% | 15.53% |
Profit Margin | 13.47% | 12.49% | 8.92% | 9.61% | -0.07% | 12.14% |
Free Cash Flow Margin | 8.91% | 8.26% | -12.77% | 0.90% | 10.32% | 5.99% |
EBITDA | 2,689 | 2,370 | 1,526 | 1,251 | 154.97 | 1,030 |
EBITDA Margin | 20.70% | 19.81% | 15.04% | 14.15% | 2.51% | 17.88% |
D&A For EBITDA | 341.56 | 334.66 | 247.4 | 172.11 | 180.84 | 135.35 |
EBIT | 2,348 | 2,035 | 1,278 | 1,079 | -25.87 | 895.02 |
EBIT Margin | 18.07% | 17.01% | 12.60% | 12.21% | -0.42% | 15.53% |
Effective Tax Rate | 24.68% | 24.73% | 23.61% | 23.41% | - | 24.33% |
Revenue as Reported | 13,055 | 12,024 | 10,209 | 8,911 | 6,239 | 5,811 |
Advertising Expenses | - | 1,045 | 903.01 | 850.41 | 656.01 | 437.43 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.